Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue.

JCO precision oncology·2026
Same author

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology·2026
Same author

Transformative microsystems for Cancer Diagnosis, treatment monitoring, and clinical integration: Outcomes from an NCI Workshop.

Journal of the National Cancer Institute·2026
Same author

Artificial intelligence in cancer diagnostics: a primer for clinicians and scientists.

Journal of the National Cancer Institute·2026
Same author

Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E.

JCO precision oncology·2026
Same author

Defining key criteria for microhaplotype locus selection in forensic genetics: Progress and recommendations by the Microhaplotype Working Group.

Forensic science international. Genetics·2026

Related Experiment Video

Updated: Jun 23, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Global variation in CYP2C8-CYP2C9 functional haplotypes.

William C Speed1, Soonmo Peter Kang, David P Tuck

  • 1Department of Genetics, Yale University School of Medicine, New Haven, CT 06520-8005, USA.

The Pharmacogenomics Journal
|April 22, 2009
PubMed
Summary

Global genetic variations in CYP2C8 and CYP2C9 single nucleotide polymorphisms (SNPs) show significant geographic differences. These distinct haplotype frequencies impact pharmacogenomic studies and drug interaction predictions.

Related Experiment Videos

Last Updated: Jun 23, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Pharmacogenomics
  • Human Genetics
  • Molecular Biology

Background:

  • CYP2C8 and CYP2C9 are crucial enzymes involved in drug metabolism.
  • Understanding genetic variations in these genes is essential for personalized medicine.
  • Previous studies have not fully characterized the global distribution of specific CYP2C8/CYP2C9 variants.

Purpose of the Study:

  • To investigate the global frequency distributions of 10 single nucleotide polymorphisms (SNPs) within the CYP2C8 and CYP2C9 genes.
  • To identify and analyze specific haplotypes and their geographic prevalence.
  • To assess the impact of these variations on pharmacogenomic association studies and drug interactions.

Main Methods:

  • Genotyping of 10 SNPs across approximately 132 kb of CYP2C8 and CYP2C9.
  • Analysis of genetic data from approximately 2500 individuals across 45 diverse populations.
  • Haplotype reconstruction and frequency calculation for identified variants.

Main Results:

  • Significant geographic variation was observed in the frequencies of specific CYP2C8 and CYP2C9 haplotypes.
  • One haplotype, including two CYP2C8 and one CYP2C9 coding variant, reached 10% frequency in Europe.
  • A distinct set of CYP2C8 haplotypes reached 17% frequency in Africa, with low frequencies (<1%) globally.

Conclusions:

  • The considerable geographic variation in CYP2C8/CYP2C9 haplotype frequencies complicates the interpretation of association studies.
  • These findings have significant pharmacogenomic implications, particularly for understanding drug metabolism and interactions across different populations.
  • Further research is needed to elucidate the functional consequences of these population-specific genetic variations.